Charles River Laboratories Inte found using ticker (CRL) have now 11 analysts in total covering the stock. The consensus rating is ‘Buy’. The range between the high target price and low target price is between 440 and 350 and has a mean target at 391. With the stocks previous close at 286.77 this is indicating there is a potential upside of 36.3%. The day 50 moving average is 309.15 while the 200 day moving average is 373.63. The market capitalisation for the company is $14,470m. You can visit the company’s website by visiting: https://www.criver.com
The potential market cap would be $19,729m based on the market concensus.
Charles River Laboratories International, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
